HUP0100812A3 - Alpha-hydroxy, -amino and -fluoro derivatives of betha-sulphonyl hydroxamic acids as matrix metalloproteinases inhibitors - Google Patents

Alpha-hydroxy, -amino and -fluoro derivatives of betha-sulphonyl hydroxamic acids as matrix metalloproteinases inhibitors

Info

Publication number
HUP0100812A3
HUP0100812A3 HU0100812A HUP0100812A HUP0100812A3 HU P0100812 A3 HUP0100812 A3 HU P0100812A3 HU 0100812 A HU0100812 A HU 0100812A HU P0100812 A HUP0100812 A HU P0100812A HU P0100812 A3 HUP0100812 A3 HU P0100812A3
Authority
HU
Hungary
Prior art keywords
betha
sulphonyl
alpha
hydroxy
amino
Prior art date
Application number
HU0100812A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of HUP0100812A2 publication Critical patent/HUP0100812A2/hu
Publication of HUP0100812A3 publication Critical patent/HUP0100812A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU0100812A 1997-11-21 1998-11-18 Alpha-hydroxy, -amino and -fluoro derivatives of betha-sulphonyl hydroxamic acids as matrix metalloproteinases inhibitors HUP0100812A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7265597P 1997-11-21 1997-11-21
PCT/IB1998/002154 WO1999026909A2 (en) 1997-11-21 1998-11-18 Alpha-hydroxy, -amino and -fluoro derivatives of beta-sulphonyl hydroxamic acids as matrix metalloproteinases inhibitors

Publications (2)

Publication Number Publication Date
HUP0100812A2 HUP0100812A2 (hu) 2001-08-28
HUP0100812A3 true HUP0100812A3 (en) 2002-11-28

Family

ID=22108985

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100812A HUP0100812A3 (en) 1997-11-21 1998-11-18 Alpha-hydroxy, -amino and -fluoro derivatives of betha-sulphonyl hydroxamic acids as matrix metalloproteinases inhibitors

Country Status (24)

Country Link
US (2) US20030166687A1 (hu)
EP (1) EP1037868B1 (hu)
JP (1) JP2001524462A (hu)
KR (1) KR20010032319A (hu)
CN (1) CN1168709C (hu)
AT (1) ATE232192T1 (hu)
AU (1) AU763113B2 (hu)
BG (1) BG104346A (hu)
BR (1) BR9814699A (hu)
CA (1) CA2310401A1 (hu)
DE (1) DE69811273T2 (hu)
DK (1) DK1037868T3 (hu)
EA (1) EA003585B1 (hu)
ES (1) ES2192349T3 (hu)
HU (1) HUP0100812A3 (hu)
IL (1) IL135586A0 (hu)
IS (1) IS1954B (hu)
NO (1) NO20002505L (hu)
NZ (1) NZ503997A (hu)
PL (1) PL341153A1 (hu)
PT (1) PT1037868E (hu)
TR (1) TR200001391T2 (hu)
UA (1) UA66818C2 (hu)
WO (1) WO1999026909A2 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001524462A (ja) * 1997-11-21 2001-12-04 ファーマシア・アンド・アップジョン・カンパニー マトリックスメタロプロテイナーゼインヒビターとしてのβ−スルホニルヒドロキサム酸のα−ヒドロキシ、−アミノ及びハロ誘導体
GB9927453D0 (en) * 1999-11-19 2000-01-19 Pharmacia & Upjohn Spa Crystalline and optically active form of a-hydroxy derivatives of ›-sulfonyl acid
WO2002030879A2 (en) 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
DE60138658D1 (de) * 2000-09-29 2009-06-18 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine Amidgruppe zur Behandlung von Malaria
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
DE10320453A1 (de) * 2003-05-08 2004-11-25 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Bioisostere von Actinonin
WO2007070760A2 (en) * 2005-12-15 2007-06-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
EP2081905B1 (en) * 2006-07-28 2012-09-12 Boehringer Ingelheim International GmbH Sulfonyl compounds which modulate the cb2 receptor
JP5030114B2 (ja) * 2006-09-25 2012-09-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体をモジュレートする化合物
US7539361B2 (en) * 2006-10-05 2009-05-26 Harris Corporation Fiber optic device for measuring a parameter of interest
DE102006049618A1 (de) * 2006-10-20 2008-05-08 Tschesche, Harald, Prof. Dr. Triazine und Ihre Verwendung als Metalloproteinase-Inhibitoren
EP2217565B1 (en) * 2007-11-07 2013-05-22 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
US8178568B2 (en) * 2008-07-10 2012-05-15 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the CB2 receptor
KR20110063438A (ko) * 2008-09-25 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 Ｃｂ2 수용체를 선택적으로 조절하는 설포닐 화합물
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
US8383615B2 (en) 2009-06-16 2013-02-26 Boehringer Ingelheim International Gmbh Azetidine 2-carboxamide derivatives which modulate the CB2 receptor
JP2013505295A (ja) * 2009-09-22 2013-02-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を選択的に調節する化合物
JP2013517271A (ja) 2010-01-15 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
JP5746228B2 (ja) 2010-03-05 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を選択的に調節するテトラゾール化合物
US8846936B2 (en) 2010-07-22 2014-09-30 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the CB2 receptor
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
DK3013796T3 (da) * 2013-06-27 2020-03-16 Lg Chemical Ltd Biarylderivater som gpr120-agonister
RU2748835C1 (ru) 2017-11-27 2021-05-31 Совет Научных И Прикладных Исследований Индол(сульфонил)-n-гидроксибензамидные производные в качестве селективных ингибиторов hdac

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE225343T1 (de) * 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
DK0871439T3 (da) 1996-01-02 2004-08-02 Aventis Pharma Inc Substituerede (aryl, heteroaryl, arylmethyl eller heteroarylmethyl) hydroxamsyreforbindelser
KR20000022532A (ko) 1996-06-27 2000-04-25 오노 야꾸힝 고교 가부시키가이샤 아릴(설파이드, 설폭시드 및 설폰)유도체 및 이를 활성 성분으로 함유하는 약물
DE69729007T2 (de) 1996-08-07 2005-04-07 Darwin Discovery Ltd., Slough Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung
CZ92399A3 (cs) * 1996-09-27 1999-07-14 Pharmacia & Upjohn Company ß-sulfonylhydroxamové kyseliny jako inhibitory matriční metaloproteinázy
AU5337498A (en) * 1997-01-22 1998-08-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted beta-thiocarboxylic acids
AU5493598A (en) 1997-02-07 1998-08-26 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
US6362183B1 (en) * 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
CN1253474A (zh) * 1997-03-04 2000-05-17 孟山都公司 磺酰基二价芳基或杂芳基异羟肟酸化合物
JP2001524462A (ja) * 1997-11-21 2001-12-04 ファーマシア・アンド・アップジョン・カンパニー マトリックスメタロプロテイナーゼインヒビターとしてのβ−スルホニルヒドロキサム酸のα−ヒドロキシ、−アミノ及びハロ誘導体

Also Published As

Publication number Publication date
WO1999026909A2 (en) 1999-06-03
CA2310401A1 (en) 1999-06-03
CN1278247A (zh) 2000-12-27
PT1037868E (pt) 2003-06-30
AU763113B2 (en) 2003-07-10
BG104346A (en) 2001-01-31
US20030166687A1 (en) 2003-09-04
HUP0100812A2 (hu) 2001-08-28
EP1037868B1 (en) 2003-02-05
ATE232192T1 (de) 2003-02-15
NO20002505L (no) 2000-06-30
NO20002505D0 (no) 2000-05-15
PL341153A1 (en) 2001-03-26
TR200001391T2 (tr) 2000-11-21
DE69811273T2 (de) 2003-12-11
AU2540599A (en) 1999-06-15
ES2192349T3 (es) 2003-10-01
DE69811273D1 (de) 2003-03-13
US6437177B1 (en) 2002-08-20
EP1037868A2 (en) 2000-09-27
UA66818C2 (uk) 2004-06-15
KR20010032319A (ko) 2001-04-16
EA003585B1 (ru) 2003-06-26
WO1999026909A3 (en) 1999-08-26
IS5475A (is) 2000-04-28
IL135586A0 (en) 2001-05-20
BR9814699A (pt) 2000-10-03
EA200000551A1 (ru) 2000-10-30
DK1037868T3 (da) 2003-05-12
CN1168709C (zh) 2004-09-29
IS1954B (is) 2004-10-13
JP2001524462A (ja) 2001-12-04
NZ503997A (en) 2001-09-28

Similar Documents

Publication Publication Date Title
HUP0100812A3 (en) Alpha-hydroxy, -amino and -fluoro derivatives of betha-sulphonyl hydroxamic acids as matrix metalloproteinases inhibitors
PL341031A1 (en) Derivatives of hydroxamic acid as inhibitors of matrix metaloprotease (mmp)
HUS1400042I1 (hu) Szulfonamid-származékok mint aszpartil-proteáz inhibitorok prodrugjai
IL129147A0 (en) The preparation and use of ortho-sulfonamide aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
IL129148A0 (en) The preparation and use of ortho-sulfonamide aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
NZ304689A (en) Lactam-containing hydroxamic acid derivatives and use as matrix metalloprotease (mmp) inhibitors
IL136812A0 (en) Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
AU5493598A (en) N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
HUP9902083A3 (en) Sulfonamide inhibitors of matrix metalloproteinases
DK0925303T3 (da) Phosphinsyreamider som matrixmetalloproteaseinhibitorer
AU4074799A (en) Substituted aryl hydroxamic acids as metalloproteinase inhibitors
ZA989064B (en) Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
HK1045501A1 (zh) 作為基質金屬蛋白酶抑制劑的異羥肟酸衍生物
PL337725A1 (en) Inhibitors of proteases
IL139248A0 (en) Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
HUP9904664A3 (en) Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors
PL342661A1 (en) Application of thiadiazole compounds as inhibitors of enzymes being dependent on cystein activity
IL115995A0 (en) Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
HRP970247B1 (en) Substituted 4-arylbutric acid derivatives as matrix metalloprotease inhibitors
AU2003204411A1 (en) alpha -hydroxy, -amino and -fluoro derivatives of beta-sulphonyl hydroxamic acids as matrix metalloproteinases inhibitors
HRP970246A2 (en) Substituted oxobutric acids as matrix metalloprotease inhibitors
IL143713A0 (en) Reverse hydroxamate inhibitors of matrix metalloproteinases
GB9708133D0 (en) Novel use of matrix metalloproteinase inhibitors
SI1001930T1 (en) N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
SI1036062T1 (en) Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors